Kymera Investor Presentation Deck

Immunology Oncology KYMERA Upcoming Milestones and Events KT-474/SAR444656 Pipeline Update KT-333 KT-253 ©2023 KYMERA THERAPEUTICS, INC. Dose first patient in Phase 2 AD trial in 4Q 2023 Estimated enrollment completion in Phase 2 HS & AD trials in 4Q 2024 Topline data expected for both studies in 1H 2025 Virtual Immunology R&D Day: January 4, 2024 Poster presentation at ASH 2023 on clinical activity: December 10, 2023 Complete Phase 1a trial in 1H 2024 Phase 1 data at medical meeting in 2024 Patient stratification and development strategy at medical meeting in 2024 Phase 1 data at medical meeting in 2024 PAGE 40

View entire presentation